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Abstract
Healthcare-related infections caused by extended-spectrum beta-lactamase (ESBL)-pro-
ducing Klebsiella spp. are of major concern. To control transmission, deep understanding of
the transmission mechanisms is needed. This systematic review aimed to identify risk fac-
tors and sources, clonal relatedness using molecular techniques, and the most effective
control strategies for ESBL-producing Klebsiella spp. A systematic search of PubMed,
Embase, and Outbreak Database was performed. We identified 2771 articles from Novem-
ber 25th, 1960 until April 7th, 2014 of which 148 were included in the systematic review and
23 in a random-effects meta-analysis study. The random-effects meta-analyses showed
that underlying disease or condition (odds ratio [OR] = 6.25; 95% confidence interval [CI] =
2.85 to 13.66) generated the highest pooled estimate. ESBL-producing Klebsiella spp. were
spread through person-to-person contact and via sources in the environment; we identified
both monoclonal and polyclonal presence. Multi-faceted interventions are needed to pre-
vent transmission of ESBL-producing Klebsiella spp.
Introduction
Healthcare-related infections (HRIs) are a major clinical problem worldwide. In 2011, the
World Health Organization (WHO) reported that in a mixed patient population the pooled
HRI-prevalence was 10.1% in low- and middle-income countries and 7.6% in high-income
countries [1]. Prolonged hospital stay, higher costs, increased antimicrobial resistance, and risk
of potentially life-threatening conditions indicate the enormous burden of HRIs [2]. Further,
we are facing HRIs caused by multidrug-resistant gram-negative bacteria (MDR-GNB) without
a parallel progression of the novel antibiotic classes [3].
Klebsiella spp. have been recognized as the most frequent cause of MDR-GNB outbreaks,
particularly after the emergence of the extended-spectrum beta-lactamase (ESBL) enzymes [4,
5]. As a result, infections in hospitalized patients with this ESBL-producing Klebsiella spp. have
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raised public concern due to the clinical outcomes and limited antibiotic options [6]. Patients
whose care requires devices, and patients who are identified with multiple antibiotic-resistant
strains in the intensive care unit (ICU) are at highest risk to acquire an infection with an ESBL-
producing Klebsiella spp. [7, 8]. High discriminatory subtyping methods are beneficial to deter-
mine clonality of the outbreak strains with pulsed-field gel electrophoresis (PFGE) as the well-
known ‘gold standard’ for molecular epidemiological studies and for current clinical use [9].
It requires deep understanding of all outbreaks to optimally control transmission of ESBL-
producing Klebsiella spp. [10]. Recent guidelines about the management of MDR-GNB under-
score the need of well-managed and multi-faceted interventions [11]. Therefore, it is necessary
to investigate the transmission dynamics and the risk factors for hospital outbreaks. This sys-
tematic review aimed to answer the following four questions. First, what are the risk factors for
the presence of ESBL-producing Klebsiella spp.? Second, what are the main sources and reser-
voirs for this microorganism? Third, how can we identify the transmission patterns and the
clonal relatedness among isolates from patients who acquired ESBL-producing Klebsiella spp.?
Fourth, what are the most effective control strategies for ESBL-producing Klebsiella spp.?
Materials and Methods
This systematic review and meta-analysis followed the guidelines outlined in the PRISMA
statement (S1 File)[12].
Search Strategy and Selection Criteria
We searched PubMed, Embase, and the Outbreak Database (until April 7th, 2014) to identify
studies which examined the transmission of multidrug-resistant (MDR) Klebsiella spp., identi-
fied potential risk factors, described modes of transmission, described laboratory methods used
for the identification, and described the effective interventions to prevent transmission of
MDR Klebsiella spp. with using the terms as applied in S2 File. The search strategy was not lim-
ited by language, date of publication, country, study design, enzyme type, or patient character-
istics. We excluded studies about: 1) pathogenesis, validation of molecular techniques, drug
options, cost, 2) non-human studies, 3) studies only about carriers, health-care workers
(HCWs), or family members, 4) studies only about environmental contamination, 5) case
report with no statement on transmission, 6) non-hospital studies, 7) letters, editorials, com-
munications, weekly reports, and reviews. However, we also searched the eligible citations of
all relevant reviews. TCH initiated full searches and AFV independently repeated the search
for a 5 percent subset of articles.
Data Extraction
We first screened all articles based on titles and abstracts and then we subsequently assessed
the articles in full text according to the inclusion and exclusion criteria. TCH initiated the
screening and extracted the data with help of AFV and MCV. To retrieve articles that could
not be found in full-text, we contacted first authors or corresponding authors of 80 publica-
tions. We also contacted the authors of 16 publications to obtain missing information about
associated factors and cluster analyses. We defined the categories of MDR Klebsiella spp. as
ESBL, possible ESBL and non-ESBL. We used the ESBL definition according to group 2b Bush
criteria [13]. We found several articles that showed resistance to cephalosporins before the
term ‘ESBL’ was established in 1989 [14]. These studies were included as being ‘ESBL’. Ulti-
mately, we only focused on studies about ESBL-producing Klebsiella spp. within one hospital.
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Data Analyses
We included articles related to ESBL-producing Klebsiella spp. that described the factors asso-
ciated with the presence or acquisition of ESBL-producing Klebsiella spp. using a multivariate
model. We took into account studies that have suggested and proven the sources of ESBL-pro-
ducing Klebsiella spp. using molecular typing techniques. However, we also included studies
that suggested the potential reservoirs. In addition, we included studies about the associated
factors for mortality related to ESBL-producing Klebsiella spp.
In order to assess clonal relatedness and transmission patterns of ESBL-producing Klebsiella
spp., studies that only performed phenotypic typing methods were excluded and studies that
did use molecular typing were included. We merged studies that used polymerase chain reac-
tion (PCR)-based techniques for typing. We assessed the result of molecular typing methods
and calculated the total number of identified patterns. We defined a cluster as two similar
patterns of ESBL-producing Klebsiella spp. isolates. Likewise, a unique isolate was defined as a
single pattern. The term monoclonal presence referred to a single cluster and the term poly-
clonal presence referred to two clusters. We calculated the total number of patterns, the clus-
ters including cluster sizes, and the single patterns. If the information was available, we
performed the cluster analyses based on the number of patients, otherwise on the number of
isolates. We also reviewed studies about infection control strategies and prevention programs.
We assessed the standard interventions possibly combined with additional control strategies,
and reported which were most successful strategies to stop transmission. We compiled data
from two studies that were presented in four publications in the result section [15–18].
Statistical Analysis
We combined all associated factors that reported an odds ratio (OR) and a 95% confidence
interval (95% CI) into ten different categories: 1, medical devices (e.g. mechanical ventilation,
intra-vascular devices); 2, prior cephalosporin exposure; 3, prior quinolone exposure; 4, prior
other antibiotic exposure; 5, prior antifungal exposure; 6, length of hospital stay; 7, patient
characteristics (e.g. age); 8, underlying disease or condition (e.g. malignant disease); 9, medical
procedures (e.g. surgical intervention); 10, other (e.g. exposure to the hands of HCWs). Studies
reporting associated factors for mortality were excluded. Random-effects meta-analyses were
performed for all categories except the “prior antifungal exposure”, “medical procedures”
which had less than three factors and “other” that comprised many various factors. Lytsy et al.,
used three different models of multivariable analyses to find reliable estimates for the most
important variables. However, we chose to only include model 1 in our meta-analyses [18]. We
applied the method of DerSimonian and Laird and meta-analyses were performed using Stats-
Direct statistical software (StatsDirect, Version 2.8.0, Altrincham, StatsDirect Ltd, 2013) [19].
We considered P values<0.05 as statistically significant. Bias assessment plots were con-
structed to explore publication bias using the Egger and Begg-Mazumbdar (Kendall’s tau) indi-
cators [19, 20].
Study Quality
The methodological quality of all studies in the random-effects meta-analyses was assessed
using the strengthening the reporting of observational studies in epidemiology (STROBE)
guidelines (Table A and Table B in S3 File) or the Newcastle-Ottawa quality assessment scale
(Table A and Table C in S3 File), based on the study design [21, 22]. Furthermore, the method-
ological quality of all molecular epidemiological studies in cluster analysis was assessed by the
strengthening the reporting of molecular epidemiology for infectious disease (STROME-ID)
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guidelines (Table D in S3 File) [23]. However, the study quality was not considered as an exclu-
sion criterion.
Results
Description
We identified a total of 5,608 articles as potentially relevant when using our search strategy
(Fig 1). Of these, 835 articles met the eligibility criteria and 25 articles were retrieved from cita-
tions of interesting reviews. We received 45 full-text articles from 80 authors. We got three fur-
ther responses to the information requests that were sent to the authors of 17 articles. We
ultimately included 148 articles in this systematic review (Fig 1). Five articles were written in
Fig 1. Flow diagram of study selection for the systematic review and random-effects meta-analyses on extended-spectrum beta-lactamase-
producingKlebsiella spp. 1 Number of studies included in the review comprise the sources and reservoirs, associated factors, cluster analysis and
successful interventions. 2 No response was obtained from the first and/or corresponding authors for the requested article.
doi:10.1371/journal.pone.0140754.g001
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Spanish, one article was written in French, one article was written in Turkish and 141 articles
were written in English. The non-English articles were translated prior to data extraction. Most
studies were conducted in Europe (39.9%; n = 59) particularly in France (n = 16), followed by
Asia (18.9%; n = 28), North America (16.9%; n = 25), Africa (9.5%; n = 14), South America
(10.8%; n = 16), multiple regions: Europe and Asia (3.4%; n = 5) and Australia (0.7%, n = 1)
with 49 countries in total. All studies were published between 1991 and 2014 with study periods
of less than a month up to seven years. Thirty-one studies (20.9%) indicated the suspected or
identified index case. The study population was predominated by adult patients (45.3%,
n = 67), followed by neonates (33.1%; n = 49), pediatric patients (5.4%; n = 8), and mix groups
including the studies located in hospitals but which did not mention the study population
(16.2%; n = 24). Seventy-six percent of all studies took place at the ICU (n = 113). These studies
can be further divided in neonatal ICU (38.1%; n = 43), pediatric ICU (3.5%; n = 4), adult ICU
(48.7%; n = 55) and mix ICU units (9.7%; n = 11). However, fifty-two studies were located both
at ICU and non-ICU.
Associated Factors
We identified 26 studies reporting associated risk factors with a statistically significant OR
above one (Table 1) and seven studies reporting associated protective factors with a statistically
significant OR below one (Table 2) for the presence of ESBL-producing Klebsiella spp. In addi-
tion, four studies identified the associated factors for bloodstream infections caused by ESBL-
producing K. pneumonia (Table 1). In general, prior antibiotic exposure was the most common
associated factor in all studies. Four studies reported associated factors for mortality [24–27]. It
was published in these four studies that the presentation with septic shock had the highest
odds ratio (205.99) [24].
Eight random-effects meta-analyses
Twenty-three studies were included in the seven random-effects meta-analyses, reporting 54
associated risk factors with a statistically significant OR above one and five associated
Table 1. Associated risk factors for the presence of ESBL-producingKlebsiella spp. based onmultivariate analyses.
Associated risk factor No. of factors RE RE or RE range No. of cases (range) Studies
Underlying disease or condition 17 OR 1.04–60.60 26–292 [42]; [43]; [44]; [45](2x); [18](6x); [46]; [47](4x); [48]
Other antibiotic exposure 15 OR 1.55–95.21 10–292 [49]; [24](a); [50]; [44]; [45]; [51](a); [52]; [34]; [53]; [54]
1 HR 4.60 206 [55]
Length of hospital stay 11 OR 1.05–12.60 18–80 [35]; [43]; [51](a); [56]; [52]; [57]; [18](3x); [58](a)
1 HR 1.26 206 [55]
Medical devices 9 OR 2.11–5.23 18–292 [59](2x); [24](a); [50]; [52]; [57]; [48](3x)
Prior cephalosporin exposure 9 OR 4.51–7.60 17–88 [42]; [50]; [60](a); [18](2x); [46](3x); [58](a)
Otherb 8 OR 1.66–9.30 18–94 [61]; [35]; [45]; [52](2x); [28]; [46]; [47]
Patient characteristics 3 OR 1.14–13.10 10–48 [49]; [51](a); [16]
1 HR 1.57 206 [55]
Prior quinolone exposure 3 OR 2.86–25.37 30–78 [50]; [54]; [58](a)
Medical proceduresb 2 OR 9.34–10.35 52–60 [24](a); [53]
Prior antifungal exposureb 2 OR 5.3–12 204 [44](2x)
Abbreviations: RE, risk estimate, 2x, 3x, 4x or 6x, two, three, four or six different factors per reference.
a Bloodstream infections.
b This category was not included in a random-effects meta-analysis study.
doi:10.1371/journal.pone.0140754.t001
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protective factors with a statistically significant OR below one (Fig 1 and Table 3). The category
of underlying disease or condition (OR = 6.25; 95% CI = 2.85 to 13.66) and prior cephalosporin
exposure (OR = 4.65; 95% CI = 2.83 to 7.65) generated the highest pooled estimates (Fig 2).
The publication bias indicators showed no significant results (Table 3).
Sources and reservoirs
Fifty-seven studies identified environmental sources and/or surrounding reservoirs for ESBL-
producing Klebsiella spp. (Table 4). Contaminated sinks were the most reported sources in the
environment (13.8%; n = 4) whereas the patients were the main reservoirs (48.9%; n = 23), fol-
lowed by the hands of HCWs (25.5%; n = 12). Interestingly, one study showed food as a trans-
mission source for ESBL-producing K. pneumonia [28].
Cluster Analyses
One hundred-twenty studies described the molecular methods used to type ESBL-producing
Klebsiella spp. and the analyses of genetic similarity (Table 5). In particular for ESBL-produc-
ing K. pneumoniae, ninety-two studies used PFGE and 16 studies used PCR-based techniques
Table 2. Associated protective factors for the presence of ESBL-producingKlebsiella spp. based onmultivariate analyses.
Associated protective factor No. of factors No. of patients RE RE or RE Range Studies
Medical devices 2 206 HR 0.22–0.52 [55]
Prior penicillin+ β lactamase inhibitor exposurea 2 88 OR 0.16–0.27 [46]
Othersb 2 27–292 OR 0.22–0.50 [34]; [48]
Prior antibiotic exposurea 1 54 OR 0.003 [56]
Prior carbapenem exposurea 1 206 HR 0.22 [55]
Agec 1 47 OR 0.95 [50]
Prior cephalosporin exposure 1 204 OR 0.1 [44]
Abbreviations: RE, risk estimate; HR, hazard ratio; OR, odds ratio.
a This factor was classiﬁed in the category of prior antibiotic exposure for a random-effects meta-analysis study.
b This category was not included in a random-effects meta-analysis study.
c This factor was classiﬁed in the category of patient characteristics for a random-effects meta-analysis study.
doi:10.1371/journal.pone.0140754.t002
Table 3. Random-effects meta-analyses of the different associated risk factors and associated protective factors for the presence of ESBL-pro-
ducingKlebsiella spp. among patients in hospitals.
Associated factor No. of
factorsa
Pooled
OR
95% CI Range of OR in individual
studies
Risk of publication bias
Kendall's
tau
P
value
Egger P
value
Underlying disease or
condition
9 6.25 2.85–
13.66
1.66–60.60 0.39 0.18 2.61 < 0.01
Prior cephalosporin exposure 9 4.65 2.83–7.65 0.10–7.60 < 0.01 0.92 − 2.26 0.14
Prior other antibiotic
exposure
17 4.38 2.29–8.34 0.003–95.21 0.16 0.39 1.51 0.16
Prior quinolone exposure 3 3.91 1.83–8.34 2.86–25.37 NC NC NC NC
Medical devices 9 2.99 2.27–3.95 2.11–5.23 0.33 0.26 1.53 < 0.01
Length of hospital stay 8 1.16 1.06–1.27 1.05–12.60 0.55 0.08 3.25 < 0.01
Patient characteristics 4 1.16 0.93–1.44 0.95–13.10 < 0.01 0.75 4.11 0.18
Abbreviations: OR, odds ratio; CI, conﬁdence interval; NC, not calculated because there were too few strata.
a Only studies included that reported 95% CI and P values
doi:10.1371/journal.pone.0140754.t003
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Fig 2. Forest plots of random-effects meta-analyses: individual and pooled odds ratios for associated risk factors and associated protective
factors for presence of ESBL-producing Klebsiella spp. among patients in hospitals. * Bloodstream infections
doi:10.1371/journal.pone.0140754.g002
Table 4. Environmental sources and reservoirs for ESBL-producing Klebsiella spp., identified from
n = 57 studies.
Reservoirs or Sources No of
studies
Studies
Innate Environment
Bottles 1 [62]
Door handles, a siphon and a table 1 [36](a)
Entire unit (Intensive Care Unit) 2 [63];[64]
Hospital kitchen-screened surfaces 1 [28](a)
Incubator 2 [65](a); [52](a)
Liquid soap 2 [66](a); [67](a)
Mask 1 [68](a)
Moist surfaces near sinks and faucets 1 [69](a)
Roll boards in operating rooms 1 [70](a)
Room surface 2 [65](a); [52](a)
Single use products
A. Intravenous medication or solution
(re-used repeatedly)
2 [71](a); [72](a)
B. Intravenous glucose preparation
(multiple-dosed)
1 [62]
C. Oxygen saturation probes (re-used
repeatedly)
1 [38](a)
Sinks 4 [73](a); [65](a); [74](a); [75](a)
Suction pump located in the room of
an infected patient
1 [76](a)
Suction tube 1 [52](a)
Thermometers 2 [38](a); [77]
Two water reservoirs from humidiﬁers 1 [78](a)
Ultrasonography coupling gel
container of the emergency room
1 [79](a)
Weighing scale machine for babies 1 [80](a)
Human
Transient Hand Carriage 1 [81]
A. Patients 23 [82]; [83](a); [73](a); [84](a); [39](a); [61](a); [85](a); [86](a); [87](a);
[88]; [49](a); [89](a);[90](a); [91](a); [92](a); [93](a); [94](a); [44](a);
[95]; [96](a); [97](a); [98](a); [99](a)
B. Health Care Workers 4 [90](a); [100](a); [98](a); [101]
Food handlers 1 [28](a)
Handholding due to work overcharge 1 [102]
Hands 11 [103]; [90]; [77]; [65](a); [52](a); [57](a); [64]; [104](a); [76](a); [67](a);
[105]
Artiﬁcial nails 1 [35](a)
Onychomycosis 2 [106](a); [107]&[34](a)
C. Family (Mother to Child)
Breast milk 2 [38](a); [15](a)
Peripartum colonization of neonates 1 [79](a)
a This study proved the source or reservoir with use of a molecular typing technique.
doi:10.1371/journal.pone.0140754.t004
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Table 5. Summary of studies (n = 120) reporting cluster analyses on identified ESBL-producing Klebsiella spp. using typing techniques.
Methods No. of
Strains:
No. of
Patterns:
No. of
Clusters:
Cluster Size: Unique
Isolates
No of
Studies
Studies
Median
(Range)
Median
(Range)a
Median
(Range)
Median of
Medians (Range
of Median)
Median
(Range)
Based on the number of patients
A. K. pneumonia
PFGE 25 (2–
235)
4 (1–55) 2 (0–15) 6 (0–81) 2 (0–45) 92 [81](b,c); [108](b,c); [109]; [84](e); [39]; [79](b,c); [110]
(b,d,g); [61](b,c); [86](b,c); [87]; [88](b,c); [111](b,d,e);
[37](b,d); [90](b,c); [112]; [66](b,c); [113](b,c,l,m); [114];
[89](b,c); [78](b,c); [115](b,c); [91](b,c); [116](b,d); [102]
(b,d); [117](b,c); [118](b,c,f); [119]; [55](b,d); [120];
[100](b,c); [121](b,d); [35](b,c); [122](g,k,l,m); [123];
[106](b,c); [77](b,d); [92](b,d); [93](b,d); [122](g,k,l,m);
[123]; [106](b,c); [77](b,d); [92](b,d); [93](b,d); [25](m);
[65](e); [80](b,c); [44]; [124](b,c); [125]; [126]; [127](g);
[57]; [128]; [96](b,d); [17] and [18](b,c,e,i); [129](b,d);
[60](g); [130](b,d); [131](b,c); [97](b,d,e,l,m); [132](b,d);
[133](e); [27](e); [98](e,m); [134]; [104](b,c); [135]; [53]
(l,m); [136](b,d); [137]; [138]; [139](b,d); [76](b,d); [28]
(b,d); [140](g); [141]; [142](b,c); [72](b,c,m); [143](b,d);
[144]; [145]; [15] and [16] (b,d,i); [47](b,c); [75](b,c);
[146](b,c); [147]; [148](l); [149](b,c); [150](b,d); [151];
[152](b,c,e); [153](b,d,g,k,l,m)
PCR 24 (4–
295)
4 (1–125) 1 (0–10) 5.5 (1–87) 2.5 (0–21) 16 [154](b,d,e); [39]; [155](b,c); [156](b,c); [117](2x,b,c,n);
[157](b,c); [44]; [80](b,c); [158](b,c,g); [159](m); [160]
(b,d); [99](b,c); [101](e,g); [161](e); [162](g); [150](b,c)
RAPD 18 (8–40) 3 (1–17) 1 (1–4) 11 (7–19) 1 (0–15) 7 [85](b,c); [49](b,c); [38](b,c); [37](b,d); [115](b,c); [100]
(b,c); [163](b,d)
MLST 21.5 (1–
46)
2.5 (1–15) 2 (0–3) 2 (0–19) 1 (0–13) 7 [164]; [134]; [136](h); [15] and [16](b,d,i); [162](g);
[150](b,d,l); [165](b,f)
Ribotyping 18 (8–57) 5.5 (1–15) 2 (1–6) 6 (2–14) 2.5 (0–9) 6 [103](b,d); [73](b,c); [166](b,d); [154](b,d,e); [77](b,d);
[128]
ME-AFLP 8 (-) 1 (-) 1 (-) 8 (-) 0 (-) 1 [70](b,c)
MLEE 19 (-) 11 (-) 1 (-) 9 (-) 10 (-) 1 [167](b,c)
B. K. Oxytoca
PFGE 2 (1–101) 1 (1–27) 1 (0–3) 1 (0–8) 1 (0–24) 7 [37](b,c); [122](g); [125]; [126]; [129](b,c); [139](b); [74]
(b,d,l)
RAPD 2 (-) 1 (-) 1 (-) 2 (-) 0 (-) 1 [37](b,c)
Based on the number of clinical strains
A. K. pneumonia
PFGE 24.5 (18–
31)
2 (2–2) 2 (1–2) 11 (9–13) 0 (0) 3 [168](b,c,m); [165](b,f); [169](b,d,f)
RAPD 37 (-) 28 (-) 6 (-) 2 (-) 22 (-) 1 [94](f)
B. K. oxytoca
PFGE 13 (3–23) 5 (1–9) 1 (0–2) 3.5 (0–7) 1 (1–1) 2 [69](f); [165](b,f)
Based on the number of patients or clinical strains + family and/or environmental strains
K. pneumonia
PFGE 49 (30–
49)
10 (2–25) 7 (2–7) 7 (2–15) 3 (0–18) 3 [163](b,d); [170](b,d,e); [36](b,d,f)
PCR 39 (30–
48)
9.5 (2–17) 3 (2–4) 15 (-) 6.5 (0–13) 2 [51](j,l); [36](b,d,f)
(Continued)
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which were predominated by enterobacterial repetitive intergenic consensus sequence–poly-
merase chain reaction (ERIC-PCR) in seven studies. Multilocus sequence typing (MLST) was
performed in seven studies as well as random amplified polymorphic DNA (RAPD). Nineteen
studies performed more than one molecular method to analyze clusters. The average number
of patients in the 120 studies was 22.5 (ranging from 1 to 295 patients). The median range of
the number of patterns was 1 to 10 (median range of cluster-size medians from 1 to 15). In 111
studies that provided both number of clusters and the cluster size based on the number of
patients, the median number of clusters was 2 ranging from 0 to 15 and the median of the clus-
ter-size medians was 6 with a range of 0 to 81. In particular for K. pneumoniae, the median
number of clusters was 2 and the median of cluster-size medians was 6. Further, the median
number of clusters and the median of the cluster-size medians were 0 for K. oxytoca. Three sur-
veillance studies reported an identical pattern indicating the clonality of identified ESBL-pro-
ducing Klebsiella spp. strains in hospitals. In particular for the outbreak events, 43 studies
showed monoclonal and 34 studies showed polyclonal presence of ESBL-producing Klebsiella
spp. among patients within the hospital.
Effective Interventions
The identification of ESBL-producing Klebsiella spp. transmission in hospitals should be fol-
lowed by infection control strategies. However, not all studies provided detailed information
Table 5. (Continued)
Methods No. of
Strains:
No. of
Patterns:
No. of
Clusters:
Cluster Size: Unique
Isolates
No of
Studies
Studies
Median
(Range)
Median
(Range)a
Median
(Range)
Median of
Medians (Range
of Median)
Median
(Range)
Raman
spectroscopy
30 (-) 2 (-) 2 (-) 15 (-) 0 (-) 1 [36](b,d,f)
Abbreviations: PFGE, pulsed-ﬁeld gel electrophoresis; PCR, polymerase chain reaction (ERIC-PCR, enterobacterial repetitive intergenic consensus
sequence; AP-PCR, arbitrarily primed-PCR; REP-PCR, repetitive sequence-based PCR; BOX-PCR; IRS-PCR, infrequent-restriction-site PCR;
RFLP-PCR, restriction fragment length polymorphism); RAPD, random ampliﬁed polymorphic DNA; MLST, multi-locus sequence typing; ME-AFLP, multi-
enzyme ampliﬁed fragment length polymorphism; MLEE, multilocus enzyme electrophoresis; (-), Only 1 study was reported
2x, This study performed two rounds of ERIC-PCR on a different dataset.
a We assessed the result of molecular typing methods and reported the total number of identiﬁed patterns as number of patterns
b Outbreak
c Monoclonal
d Polyclonal
e The number of patients were not literally written
f Number of clinical isolates for cluster analysis due to available data or different time points of the isolates
g Different presentation of data between text and ﬁgures on papers, hence we used data from the ﬁgures (except Liu 1998, Lavigne 2004, Wu 2006 and
Cassettari 2009)
h MLST was only performed on the index patient
i Two publications used same isolates, hence, we combined the data
j This study was performed on 48 patient samples that consisted of 46 healthcare-related infections and 2 unidentiﬁed samples
k Data of number of patterns was not available
l Data of cluster size was not available
m Data of unique isolates was not available
n Data of unique isolates on the second round was not available.
doi:10.1371/journal.pone.0140754.t005
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regarding the interventions. We identified 84 studies that described the interventions during
the study period. Twenty-eight studies reported the standard interventions that did not suc-
ceed. All but three studies described the additional and/or successful strategies to prevent the
spread of ESBL-producing Klebsiella spp. in hospitals. Ultimately, we presented the top ten
strategies to control ESBL-producing Klebsiella spp. in hospitals from 71 studies (Table 6).
Reinforcement of hand hygiene (46.5%) was the most successful intervention in all studies, fol-
lowed by adequate compliance with the antibiotic control programs (33.8%). Removal of con-
taminated tools was also found in the list of top 10 strategies to control ESBL-producing
Klebsiella spp. infections within the hospital.
Discussion
Summary of evidence
This is the first systematic review and meta-analyses to identify the transmission pattern of
ESBL-producing Klebsiella spp. among hospitalized patients worldwide. Our random-effects
meta-analyses showed the underlying disease including malignancy or particular condition
(OR = 6.25; 95% CI = 2.85 to 13.66) and prior cephalosporin exposure (OR = 4.65; 95%
CI = 2.83 to 7.65) as the most significant associated factors for the presence of ESBL-producing
Table 6. Top 10 strategies to control ESBL-producingKlebsiella spp. outbreaks in hospitals.
No. Intervention No. of
studies
Studies
1 Reinforcement of hand hygiene 33 [103]; [171]; [81]; [73]; [85]; [86]; [172]; [88]; [155]; [166]; [49];
[90]; [66]; [115]; [116]; [168]; [102]; [35](a); [77]; [92]; [157]; [62]
(a); [65]; [94](a); [80]; [44]; [95]; [64](a); [76];[67](a); [15]; [149];
[152]
2 Control of antibiotic use 24 [171]; [61]; [86]; [155]; [49]; [66]; [116]; [168]; [102]; [42]; [65];
[80]; [44]; [51]; [95]; [57]; [96](a); [76]; [67](a); [99]; [101]; [165];
[169]; [152]
3 Strict hygienic practices 18 [73]; [86]; [90]; [102]; [69](a); [92]; [173]; [94](a); [96](a); [131];
[76]; [141]; [15]; [47](a); [148](a); [149](a); [16]; [152]
4 a. Screening programs with an
active microbiological surveillance
15 [49]; [90]; [38](a); [92]; [57]; [96](a); [131]; [139]; [76]; [99]; [15];
[47](a); [75](a); [148](a); [169]
b. Cohorting of patients 15 [171]; [81]; [172]; [49]; [90]; [157](a); [65]; [95]; [96](a); [64](a);
[131]; [15]; [148](a); [169]; [152]
5 Single-use equipment 14 [103]; [79](a); [88]; [155]; [166]; [49]; [116]; [77]; [92]; [71]; [76];
[141]; [72](a); [15]
6 Barrier precautions 12 [108]; [86]; [90]; [120]; [157](a); [70]; [80]; [44]; [76]; [141]; [47]
(a); [152]
7 Patient isolation 11 [73]; [85]; [155]; [49]; [90]; [102]; [95]; [76]; [36](a); [15]; [149]
(a)
8 Good cooperation between
department and infection control
team
9 [49]; [71]; [65]; [95]; [96](a); [131]; [142]; [149](a); [152]
9 Personnel educational programs 8 [88]; [90]; [66]; [71]; [80]; [95]; [76]; [169]
10 a. Removal of contaminated tools 7 [73]; [79](a); [69](a); [70]; [97](a); [15]; [75](a)
b. Temporary closure of
contaminated rooms
7 [174](a); [66]; [38](a); [92]; [94](a); [95]; [16]
c. Medical-equipment disinfections 7 [90]; [78]; [44]; [175]; [141]; [72](a); [15]
a The study added this additional intervention that was successful to control the events of ESBL-producing
Klebsiella spp. in the hospital.
doi:10.1371/journal.pone.0140754.t006
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Klebsiella spp. Consistent with our study, Cornejo-Juárez et al., indicated the increased risk of
ESBL-Escherichia coli bacteremia in patients with hematologic malignancies who had prior
cephalosporins exposure [29]. Our finding was also in line with a systematic review of ESBL-
producing Enterobacteriaceae in Latin America that reported prior antibiotic exposure, in par-
ticular cephalosporins as the associated risk factor with a statistically significant OR above one
for the acquisition of ESBL-producing Klebsiella spp. [30]. Nevertheless, based on the study by
Piroth et al., antibiotic use can be an associated protective factor with a statistically significant
OR below one [31]. Moreover, our study reported the fact that infection with ESBL-producing
Klebsiella spp. can cause fatal outcomes in association with other associated risk factors [32].
Our study confirmed the importance of interaction between hospitalized patients, environ-
mental sources, and surrounding reservoirs, in particular the HCWs. Obviously, the colonized
and/or infected patients were the consistent reservoirs (Table 1). Further, it was clear that sur-
rounding reservoirs and sources must be taken into consideration in order to end the vicious
cycle of the spread of ESBL-producing Klebsiella spp. In general, likewise in case of Methicillin-
resistant Staphylococcus aureus, HCWs who are colonized with ESBL-producing Klebsiella spp.
play a pivotal role in the transmission through their hands [33]. Even more, using artificial
nails and having onychomycosis can be the transmission source for the presence of ESBL-pro-
ducing Klebsiella spp. [34, 35].
Molecular typing. PFGE still is the gold standard for molecular typing, in particular to
prove the transmission of ESBL-producing Klebsiella spp. among patients [9]. However, it is
useful to perform another molecular technique in order to confirm the result of the main diag-
nostic technique or transmission [36, 37]. Furthermore, our findings showed that both mono-
clonal and polyclonal presence occur in outbreak events. This indicated that clonal
dissemination plays a role in outbreaks [38]. However, it is also important to consider the hori-
zontal plasmid transfer among different bacterial species [36]. Studies on plasmid fingerprint-
ing showed the importance of plasmid genotyping to predict the mode of plasmid transmission
among patients [37, 39].
Interventions. To stop the spread of ESBL-producing Klebsiella spp., reinforcement of
hand hygiene and an antibiotic control program were the most successful interventions. Firstly,
hand hygiene is a simple and low cost intervention to prevent the presence of ESBL-producing
Klebsiella spp. The introduction of hand antiseptic will reduce the contamination of the hands
with of ESBL-producing Klebsiella spp. [40]. Recent guidelines also highlight hand hygiene as
the top priority to prevent the transmission of nosocomial infections [11]. Secondly, a meta-
analysis study suggested cycling empirical antibiotic therapy to prevent antibiotic resistance
[41]. This adjustable cycling model confirmed the antibiotic control program as an important
strategy for ESBL-producing Klebsiella spp. transmission.
Study quality. Most studies included in the meta-analyses and cluster analysis had a low
study quality using the recommended guidelines. However, in particular for the studies that
were assessed with STROME-ID guidelines, they had wide range of key objectives that did not
focus solely on molecular epidemiology of ESBL-producing Klebsiella spp. Nonetheless, report-
ing the cases of ESBL-producing Klebsiella spp. according to STROME-ID guidelines can give
clear information about the evidence to detect the transmission dynamics with molecular typ-
ing and helps in making the health-policy decision. In general, the studies that were included
answered our research questions; however, our study indicated the importance to report struc-
tured articles that follow appropriate guidelines for a high study quality.
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Strengths and Limitations
The major strength of our study was the inclusion of a large number of hospitalized patients
with ESBL-producing Klebsiella spp. In the meta-analyses, we identified several risk factors
that were associated with the presence of ESBL-producing Klebsiella spp. We also summarized
the most successful interventions to prevent the spread of ESBL-producing Klebsiella spp.,
which to our knowledge has never been done before.However, our study also has some limita-
tions. Firstly, the heterogeneity of all included studies in combination with the diverse models
used in all individual statistical analyses, here combined in the meta-analyses. Therefore, we
performed a random-effects model for the meta-analyses. Secondly, due to the different defini-
tions of colonization and infection in the studies, we termed them as presence of ESBL-produc-
ing Klebsiella spp. As a consequence, reporting them separately was not possible. Thirdly, our
study focused on clonal spread; hence, we did not include studies about plasmid transfers.
Fourthly, some studies only performed molecular typing investigation on selected samples due
to cost effectiveness. Therefore, most probably we have bias on the number of clusters. Fifthly,
publication bias might have occurred since we have a broad range of articles from different
objectives to comprehensively answer our research questions.
Conclusion
The presence of ESBL-producing Klebsiella spp., which results in increased morbidity and mor-
tality, may occur by either direct spread from patient to patient or indirect transmission via
surrounding reservoirs and sources in the environment. Obviously, molecular typing tech-
niques can identify transmission of ESBL-producing Klebsiella spp. within the hospital. Prior
antibiotic exposure holds a key role for the presence of ESBL-producing Klebsiella spp. particu-
larly cephalosporin use. Multi-faceted interventions, including reinforcement of hand hygiene
and control of antibiotic use, are necessary to prevent the spread of ESBL-producing Klebsiella
spp. Further studies on plasmid transfer are needed to learn more about transmission of ESBL-
producing Klebsiella spp. within a hospital. In addition, it is important to report studies in a
more structured way that systematically follows suitable guidelines.
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